Canadian Life Science Law Blog Round-Up - July 2017

Life Sciences Law

07/13/2017       By Cameron A. Mingay, Cathy L. Mercer, Alison Hayman, A. Chandimal Nicholas, Steven Kennedy

In This Issue

  1. Major Changes Proposed to Canada’s Patented Medicines Regulations
  2. Regulatory Change to Address Antimicrobial Resistance
  3. Alternative Financing Options in the Cannabis Industry
  4. Disclosure Requirements for Non-Venture Issuers Regarding Women in Board and Executive Officer Positions – A Review
  5. Alison Hayman and Len Glickman Discuss Canadian Cannabis Law at Upcoming Cannabis Law Institute in Denver

Major Changes Proposed to Canada’s Patented Medicines Regulations

By A. Chandimal Nicholas

On May 16, 2017, the Federal Minister of Health, the Hon. Jane Philpott announced a number of proposed regulatory changes to the Patented Medicines Regulations (the "Regulations"). The proposed regulations are being implemented with the primary intent of "protecting Canadians from excessive drug prices". The proposed modernization framework constitutes the most significant suite of regulatory changes in twenty years. As noted in our blog post dated July 1, 2016, these proposed changes are part of ongoing reform to Canada's regulatory framework relating to patented drug prices.

Read more about the major changes proposed to Canada's Patented Medicines Regulations.

 

Top

Regulatory Change to Address Antimicrobial Resistance

On May 17th 2017, Health Canada announced changes to the Food and Drug Regulations regarding the use of antimicrobial drugs in animals. These changes, along with other ongoing initiatives, aim to address the increasing health concern posed by antimicrobial resistance. Microorganisms (such as bacteria, fungi, viruses and parasites) could develop resistance after exposure to antimicrobial drugs and render medicines ineffective against infections.

Read more about the regulatory change regarding the use of antimicrobial drugs in animals.

Top

Alternative Financing Options in the Cannabis Industry

By Cathy L. Mercer

The recent developments in Canadian cannabis policy and legislation have sparked significant investment in licensed cannabis producers. Until recently, equity financing has been the primary form of financing, with Canadian cannabis companies raising approximately $1 billion over the past twelve months.

Read more about the alternative financing options in the cannabis industry.

Top

Disclosure Requirements for Non-Venture Issuers Regarding Women in Board and Executive Officer Positions – A Review

By Cameron A. Mingay

On June 7, 2017, the Canadian news cycle addressed cannabis industry insider criticism at the dearth of women on boards and in senior management positions at Canadian cannabis companies, with reports suggesting that 5% of board seats at publicly traded marijuana producers are occupied by women.

To read more about the disclosure requirements for non-venture issuers regarding women in board and executive officer positions.

Top

Alison Hayman and Len Glickman Discuss Canadian Cannabis Law at Upcoming Cannabis Law Institute in Denver

Join us at the Cannabis Law Institute, a seminal two-day cannabis industry legal education event produced by the National Cannabis Bar Association and co-sponsored by the University of Denver Sturm College of Law on July 28-29, 2017 in Denver, Colorado.

Cassels Brock lawyers Alison Hayman and Len Glickman will be discussing various aspects of Canadian law in respect to the cannabis industry, including cross-border transactions, intellectual property and regulatory developments.

More information is available here about the upcoming Cannabis Law Institute in Denver.

Top